UK cost agency backs melanoma drugs after price cuts
November 2nd, 2012
LONDON | Thu Nov 1, 2012 8:01pm EDT LONDON (Reuters) – Two new drugs for skin cancer have been recommended for use on Britain’s state-run health service after the rival manufacturers – Roche and Bristol-Myers Squibb – agreed to cut their prices. The move underscores the growing pressure on drug companies to cut deals with austerity-hit European governments in order to prove their expensive new medicines offer value for money.
[Continue Reading...]
Insight: Crunching the numbers to boost odds against cancer
November 1st, 2012
A dispensing chemist prepares drugs for a chemotherapy treatment in a sterile room at Antoine-Lacassagne Cancer Centre in Nice October 18, 2012. Picture taken October 18, 2012
[Continue Reading...]
Republican candidate calls aborting rapist’s child "more violence on woman’s body"
November 1st, 2012
By Jonathan Kaminsky OLYMPIA, Washington | Thu Nov 1, 2012 12:42am EDT OLYMPIA, Washington (Reuters) – Tea Party politician John Koster, the Republican nominee for a hotly contested congressional seat in Washington state, says he opposes abortions, even in cases of “the rape thing,” because it is tantamount to inflicting “more violence onto a woman’s body.” The Snohomish County councilman made the comments during a weekend fundraising appearance in the Puget Sound city of Everett, north of Seattle, that was captured in a recording released on Wednesday by the liberal activist group Fuse Washington. Long known as an opponent of abortion, even in cases of rape or incest, Koster was asked if there were any circumstances under which he would approve of terminating a pregnancy. “When a mother’s life is in danger ..
[Continue Reading...]
Top medical innovations treat headaches, diabetes
October 31st, 2012
An Autonomic Technologies Inc. (ATI) Neurostimulator, an almond-size device that is implanted in the mouth to relief severe headaches, is pictured in this undated handout photo. The best medical innovations for next year include the device and a hand-held scanner resembling a blow dryer that detects skin cancer, the Cleveland Clinic said on October 31, 2012
[Continue Reading...]
Analysis: Employees to face healthcare sticker shock
October 28th, 2012
By Caroline Humer NEW YORK | Sun Oct 28, 2012 1:46pm EDT NEW YORK (Reuters) – Visit to New York City orthopedist: $223. One X-ray: $50. One follow-up magnetic resonance imaging test: $766.
[Continue Reading...]
FDA approves Teva leukemia drug
October 26th, 2012
Fri Oct 26, 2012 11:51am EDT (Reuters) – The U.S.
[Continue Reading...]
Novo confident in heart safety of new insulin
October 26th, 2012
By Mette Fraende and Ole Mikkelsen COPENHAGEN | Fri Oct 26, 2012 7:23am EDT COPENHAGEN (Reuters) – Novo Nordisk said it was confident about the safety of new ultra long-acting insulin degludec, after news a U.S. panel is to examine its heart risks sent the Danish group’s shares lower
[Continue Reading...]
Novo shares drop on U.S. scrutiny of insulin drug
October 26th, 2012
COPENHAGEN | Fri Oct 26, 2012 4:26am EDT COPENHAGEN (Reuters) – Shares in Denmark’s Novo Nordisk fell as much as 5 percent on Friday, after a U.S.
[Continue Reading...]
U.S. probes deaths for links to Monster energy drink
October 23rd, 2012
Two cans of Monster Energy drink are pictured in this photo-illustration shot in Los Angeles October 22,2012. Credit: Reuters/Fred Prouser By Martinne Geller and David Morgan NEW YORK/WASHINGTON | Mon Oct 22, 2012 8:37pm EDT NEW YORK/WASHINGTON (Reuters) – The Food and Drug Administration said on Monday that it was investigating reports of five deaths that may be associated with Monster Beverage Corp’s namesake energy drink, and the company’s shares fell more than 14 percent.
[Continue Reading...]
U.S. FDA panel backs Sanofi, Isis drug for rare disorder
October 18th, 2012
By David Morgan WASHINGTON | Thu Oct 18, 2012 4:29pm EDT WASHINGTON (Reuters) – A U.S. Food and Drug Administration panel of outside experts recommended the Sanofi SA and Isis Pharmaceutical Inc drug, Kynamro, for treatment of a rare genetic disorder that causes unusually high cholesterol and life-threatening cardiovascular disease. In a 9-6 vote on Thursday, the FDA advisory committee concluded that company-provided research showed the 200 milligram injection to be safe and effective enough for the one in 1 million Americans who have homozygous familial hypercholesterolemia, or HoFH, and are already on a cholesterol treatment regimen that includes lipid-lowering medication.
[Continue Reading...]
